A Second-Line Therapy for Cholangiocarcinoma Is Modestly Effective

Standard chemotherapy for metastatic cholangiocarcinoma combines gemcitabine and cisplatin, but there is no standard second-line therapy. Recently, agents with molecular targets have shown promise, including pemigatinib and ivosidenib, with pemigatinib now approved for cholangiocarcinoma harboring FGFR gene fusion or rearrangement. Investigators now report results of the ABC-06 trial, an open-label, investigator-initiated, multicenter, phase 3 trial evaluating FOLFOX (folinic acid, fluorouracil, and oxaliplatin) after disease progression in patients previously receiving gemcitabine plus cisplatin.

The 162 participants had metastatic or locally advanced disease and were randomized to either FOLFOX plus active symptom care (ASC) or ASC alone. …